Warning: The NCBI web site requires JavaScript to function. more...
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI.
Breast Cancer Res. 2007;9(4):R50.
Related citations
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI.
Endocrinology. 2003 Mar;144(3):1032-44.
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI.
Breast Cancer Res Treat. 2003 Sep;81(1):81-93.
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI.
Endocrinology. 2003 Nov;144(11):5105-17. Epub 2003 Aug 7.
Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells.
Jordan NJ, Gee JM, Barrow D, Wakeling AE, Nicholson RI.
Breast Cancer Res Treat. 2004 Sep;87(2):167-80.
Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI.
Breast Cancer Res Treat. 2006 Mar;96(2):131-46. Epub 2005 Oct 27.
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI.
Endocr Relat Cancer. 2004 Dec;11(4):793-814.
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR.
Breast Cancer Res Treat. 2008 Sep;111(1):79-91. Epub 2007 Sep 28.
[Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL, Zhu X, Zheng W, Wang XY, Wu ZY.
Ai Zheng. 2006 Jul;25(7):839-43. Chinese.
Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
Cytometry. 2001 Aug 1;44(4):338-48.
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor.
Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI.
Endocrinology. 2005 Nov;146(11):4609-18. Epub 2005 Jul 21.
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M.
Endocr Relat Cancer. 2005 Dec;12(4):983-98.
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.
Clin Cancer Res. 2006 Jul 1;12(13):4103-11.
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S.
J Cell Physiol. 2006 May;207(2):420-7.
PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Shien T, Doihara H, Hara H, Takahashi H, Yoshitomi S, Taira N, Ishibe Y, Teramoto J, Aoe M, Shimizu N.
Breast Cancer. 2004;11(4):367-73.
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
Normanno N, Campiglio M, Maiello MR, De Luca A, Mancino M, Gallo M, D'Alessio A, Menard S.
Breast Cancer Res Treat. 2008 Nov;112(1):25-33. Epub 2007 Nov 30.
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.
Int J Mol Med. 2007 Jul;20(1):3-10. Review.
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
Clin Cancer Res. 2004 Oct 1;10(19):6487-501.
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B, Crown J, Clynes M, O'Donovan N.
Ann Oncol. 2009 May;20(5):862-7. Epub 2009 Jan 15.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on